Dazucorilant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Dazucorilant Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Dazucorilant can convert its Small molecule drug profile and GR biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Dazucorilant (query alias: Dazucorilant) |
|---|---|
| Modality / target | Small molecule drug; GR; GR modulators |
| Highest global status | Phase 2 |
| Originator | Corcept Therapeutics, Inc. |
| Active developers | Corcept Therapeutics, Inc. |
The MCP disease footprint includes Amyotrophic Lateral Sclerosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05407324 | Phase 2 | Recruiting | 279 | Change from Baseline to Week 24 in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score. |
| NCT06495944 | Phase 1 | Completed | 21 | Maximum observed plasma concentration (Cmax) of dazucorilant |
| NCT06928779 | Phase 1 | Completed | 19 | Area under the concentration-time curve from time zero to the last non-zero concentration (AUC0-t) of dazucorilant |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
Phase 2; n=249; evaluation: Negative. Reported fields: ALSFRS-R = did not meet Not Met; ALSFRS-R = did not meet Not Met
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 2; n=249; evaluation: Negative. Reported fields: ALSFRS-R = DAZALS did not meet its primary endpoint Not Met; ALSFRS-R = DAZALS did not meet its primary endpoint Not Met; ALSFRS-R = DAZALS did not meet its primary endpoint Not Met
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Dazucorilant addresses Amyotrophic Lateral Sclerosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 176 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: GR records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-07-08 | Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs | Approved | Financial terms not disclosed |
| 2026-06-24 | 云顶新耀与海南合瑞达成商业化合作 | Approved | Financial terms not disclosed |
| 2026-06-09 | Lupin partners with Spain's ERN for launch of asthma, COPD inhaler Luforbec | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Treatments for amyotrophic lateral sclerosis using dazucorilant”. The milestone feed surfaced a patent-application signal described as “Treatments for amyotrophic lateral sclerosis using dazucorilant”. The milestone feed surfaced a patent-application signal described as “TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
